[Summary] One of the leading enterprises in domestic molecular diagnostic reagen
Shanghai ZJ Bio-Tech Co., Ltd. (Stock Code: 688317) is a high-tech enterprise specialized in the research, development, production, and sales of biomedical molecular diagnostic reagents and instrument equipment. In 2020, its revenue exceeded 2 billion yuan, making it one of the leading enterprises in the industry. It is also one of the few enterprises that have obtained WHO certification and been included in its official procurement list in the last three global public health emergencies.
The company has won more than 10 awards, including the National Technological Invention Award and the Industry-University-Research Cooperation Innovation Award, and has participated in over 20 national and municipal projects in Shanghai. Its product series include automated testing equipment and diagnostic reagent products, covering all legally notifiable infectious diseases in China, mainly used in medical clinical settings, public health emergencies, import and export inspection and quarantine, food inspection, and other fields.
Currently, the company is committed to the research and innovation of automated intelligent equipment, various diagnostic reagents, innovative drugs, and key raw materials, enriching its R&D product pipeline and enhancing its core competitiveness.
What does Shanghai ZJ Bio-Tech Co., Ltd. require? Who is ZJ Bio hiring? ZJ Bio recruitment: 销售类占比最多占70.1%,其次是医疗卫生/美容保健类占21%. What education can get in at ZJ Bio? 大专占比最多占50.3%,其次是本科占28.7%. High education required at ZJ Bio? 硕士占10.2%,博士占8.4%. Work experience required at ZJ Bio? 不限占比最多占37.1%,其次是3-5年占31.1%. Where are the job locations at ZJ Bio? 上海占比最多占49.7%,其次是北京占4.8%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows